Proactive Investors - Run By Investors For Investors

Horizon Discovery shares soar as it rejects £270mln takeover approach from antibodies group Abcam

Abcam said it made a proposal to the board of Horizon Discovery on 19 April 2018 in relation to a possible all share offer which would value each Horizon share at 181p
Biotech firm
It added that the proposal has today been rejected by the Horizon Discovery board

Horizon Discovery Group PLC (LON:HZD) shares soared 30% on Wednesday after antibodies group Abcam PLC (LON:ABC) revealed it has had a £270mln takeover approach to the biotech firm rejected.

In late afternoon trading, Horizon Discovery shares were up 30.6% at 188p, while Abcam shares gained 2.2% at 1,240p.

READ: Abcam raises revenue guidance after Roche deal

In a statement, Abcam said it made a proposal to the board of Horizon Discovery on 19 April 2018 in relation to a possible all share offer which would value each Horizon Discovery ordinary share at 181p each.

It added that the proposal has today been rejected by the Horizon Discovery board.

Abcam said it “believes that the Proposal represents a compelling opportunity to drive superior value creation for the shareholders of both companies.”

“Accordingly,” it added, “Abcam is seeking to engage with Horizon Discovery in a constructive dialogue and is announcing the Proposal as a means to encourage and further that process.”

The group said; “Abcam is executing its vision to be the most influential life science company for researchers worldwide. Horizon Discovery has developed extensive capabilities in the gene editing market and the Board of Abcam believes that the combination of Horizon Discovery's business with Abcam would assist both Abcam and Horizon Discovery to expand their reach and influence globally.”

View full HZD profile View Profile

Horizon Discovery Group PLC Timeline

Related Articles

test tubes
April 16 2019
Summit Therapeutics' potential breakthrough targets C.difficile
technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
Cameron Durrant
March 04 2019
A goal is to improve the safety of CAR-T therapies, used in the treatment of children with acute lymphoblastic leukemia and adults with advanced lymphomas

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use